A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors
PHASE1CompletedINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
November 30, 1995
Study Completion Date
October 31, 2000
Conditions
Neoplasms
Interventions
DRUG
irinotecan (CPT-11)
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00001495 - A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors | Biotech Hunter | Biotech Hunter